L-Carnitine
Evidence: A/D — Established Human EvidenceMetabolic / Weight Management
Evidence Snapshot
What this grade covers
Strong regulatory/human evidence applies specifically to the FDA-approved deficiency indications (primary carnitine deficiency, dialysis-associated deficiency, inborn errors of metabolism). Evidence for the general wellness, fat-loss, or athletic-performance claims commonly marketed alongside L-Carnitine products is weak or absent from the sources reviewed here.
Regulatory Context
FDA-approved (as levocarnitine, brand CARNITOR) for treatment of primary systemic carnitine deficiency, prevention/treatment of carnitine deficiency in end-stage renal disease patients undergoing dialysis, and acute/chronic treatment of carnitine deficiency secondary to inborn errors of metabolism. These are the only FDA-approved indications; general use in healthy individuals for weight loss or athletic performance is not FDA-approved and is not supported by the evidence reviewed here.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
A small, non-peptide, naturally occurring compound (a quaternary ammonium betaine derived from lysine/methionine metabolism) that the body makes in small amounts and also obtains from meat and dairy. Its drug form is levocarnitine.
Why are researchers interested in it?
Carnitine is required for mitochondrial fatty-acid oxidation via the carnitine shuttle, so it has been studied both as a drug for genuine carnitine-deficiency states and, separately, marketed as a wellness/weight-management supplement -- these two bodies of evidence are not the same.
What does the evidence look like?
The mitochondrial-transport mechanism and human pharmacokinetics are well established. Its FDA-approved indications rest on regulatory/clinical evidence for specific deficiency conditions. Broader fat-loss or performance claims made for general supplement use are not supported by the sources reviewed here.
Biggest things to know
It is a small-molecule metabolite, not a peptide. Its FDA approval is for defined deficiency states, not for weight loss or performance in healthy people. A supplier's research-use L-Carnitine vial is not shown by that approval to share the same formulation, purity, or regulatory status as the approved drug CARNITOR.
What don't we know yet?
The sources reviewed here do not establish an effective or safe dose, protocol, or outcome for using L-Carnitine as a fat-loss or performance aid in people who are not carnitine-deficient.
Research Takeaway
L-Carnitine (levocarnitine) is a naturally occurring quaternary ammonium compound derived from lysine/methionine metabolism, not a peptide.
See all 6 evidence claims →Quick Summary
L-Carnitine (levocarnitine) is a naturally occurring, non-peptide quaternary ammonium compound essential for shuttling long-chain fatty acids into mitochondria for beta-oxidation. It is FDA-approved as an injectable and oral drug for specific carnitine-deficiency conditions. Foundational biochemistry and human pharmacokinetic literature describe how it is absorbed, transported, and used, but the sources reviewed here do not establish weight-loss, fat-burning, or athletic-performance benefits in people who are not carnitine-deficient.
Mechanism & Research Overview
Long-chain fatty acids cannot cross the inner mitochondrial membrane unassisted. Carnitine palmitoyltransferase I (CPT1), on the outer mitochondrial membrane, forms acylcarnitine esters from long-chain fatty acids and carnitine. Carnitine-acylcarnitine translocase then exchanges acylcarnitine for free carnitine across the inner membrane, and carnitine palmitoyltransferase II (CPT2) regenerates acyl-CoA in the matrix for beta-oxidation -- together, the carnitine shuttle. Cellular carnitine uptake, especially in cardiac and skeletal muscle, depends on the high-affinity OCTN2 transporter. Whole-body carnitine levels are maintained by a combination of modest endogenous synthesis (liver, kidney, and in some species the brain) and efficient renal reabsorption of circulating carnitine.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
L-Carnitine (levocarnitine) is a naturally occurring quaternary ammonium compound derived from lysine/methionine metabolism, not a peptide.
Sources: Carnitine--metabolism and functions; Carnitine transport and fatty acid oxidation
Supported
Carnitine enables transfer of long-chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle (CPT1, carnitine-acylcarnitine translocase, CPT2), making them available for beta-oxidation.
Sources: Carnitine transport and fatty acid oxidation; Carnitine--metabolism and functions
Supported
In humans, dietary L-carnitine is absorbed with roughly 54-87% bioavailability, while supplement-dose L-carnitine (0.5-6 g) is absorbed largely by passive transport with only about 14-18% bioavailability; whole-body carnitine turnover time is roughly 38-119 hours at normal dietary intake.
Sources: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism
Supported
FDA has approved levocarnitine (CARNITOR) for treatment of primary systemic carnitine deficiency, prevention/treatment of carnitine deficiency in patients with end-stage renal disease undergoing dialysis, and acute/chronic treatment of carnitine deficiency secondary to inborn errors of metabolism.
Sources: CARNITOR (levocarnitine) Injection -- FDA Prescribing Information (NDA 20-182)
Supported
These FDA-approved indications apply to defined carnitine-deficiency states and do not establish that L-Carnitine supplementation causes fat loss, improves exercise performance, or provides benefit in individuals who are not carnitine-deficient.
Sources: CARNITOR (levocarnitine) Injection -- FDA Prescribing Information (NDA 20-182); Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism
Supported
The FDA label for injectable levocarnitine describes a specific sterile aqueous drug formulation dosed under medical supervision for defined deficiency indications; this does not establish the identity, purity, sterility, or safety of an unspecified vendor research-use L-Carnitine product.
Sources: CARNITOR (levocarnitine) Injection -- FDA Prescribing Information (NDA 20-182)
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The sources reviewed establish mitochondrial fatty-acid-transport biochemistry and FDA-approved deficiency indications, not weight-loss, fat-burning, or athletic-performance benefits in healthy people.Safety Consideration
FDA's approval covers the specific CARNITOR drug product and its approved deficiency indications; a supplier's L-Carnitine vial is not shown by that approval to share the same formulation, purity, sterility, or regulatory status.Safety Consideration
Any dosing described in the FDA label or cited literature reflects treatment of a diagnosed carnitine-deficiency condition under medical supervision, not a recommendation for general or research use.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| CARNITOR (levocarnitine) Injection -- FDA Prescribing Information (NDA 20-182) | FDA-approved indications for levocarnitine (CARNITOR) Injection: treatment of primary systemic carnitine deficiency; prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing dialysis; and acute and chronic treatment of patients with an inborn error of metabolism resulting in secondary carnitine deficiency. No indication covers weight loss, fat-burning, or athletic performance in individuals without a diagnosed deficiency. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Carnitine transport and fatty acid oxidation | 2016 | Carnitine is essential for transfer of long-chain fatty acids across the inner mitochondrial membrane, via carnitine palmitoyltransferase I/II and carnitine-acylcarnitine translocase (the carnitine shuttle), making them available for beta-oxidation. The high-affinity OCTN2 transporter mediates cellular carnitine uptake, especially in cardiac and skeletal muscle; defective OCTN2 activity reduces carnitine levels and impairs fatty-acid oxidation. | |||
| Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism | 2004 | Human (review synthesizing human absorption/kinetics data) | Human dietary L-carnitine is absorbed with roughly 54-87% bioavailability depending on meal content; supplement-dose L-carnitine (0.5-6 g) is absorbed largely by passive transport with only about 14-18% bioavailability. Circulating carnitine distributes to a large slow-turnover compartment (muscle) and a smaller rapid-turnover compartment (liver, kidney, other tissues); whole-body turnover time is roughly 38-119 hours at normal dietary intake. Carnitine homeostasis is maintained by diet, modest endogenous synthesis, and efficient renal reabsorption. | ||
| Carnitine--metabolism and functions | 1983 | Foundational biochemical review establishing carnitine's central role in fatty-acid metabolism, and describing endogenous carnitine biosynthesis (lysine methylation to trimethyllysine, conversion to butyrobetaine, hydroxylation to carnitine in liver and, in some species, kidney). |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
This page describes L-Carnitine's mitochondrial fatty-acid-transport biochemistry and its FDA-approved use (as levocarnitine) for specific carnitine-deficiency conditions. It is not evidence that L-Carnitine causes fat loss or improves performance in healthy people, and it is not dosing guidance.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-09-07.
Follow research updates for L-Carnitine
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.